Latest News
& Press Releases
Browse the latest news from BioSpace, and press releases from around the industry. Want to filter by date, keyword, and more? Search here.
TOP STORIES
Research on obesity is essential, as it can lead to serious health consequences. Researchers are now turning to the immune system for answers about the condition.
Effective communication skills are vital for success in the pharma industry. Here are some tips to help you improve your communication skills.
Public health officials begin to think we’ve turned the corner on the pandemic as new global cases drop 21% last week, the third consecutive week numbers and deaths have declined.
The DSMB endorsed the use of mRNA-1345 for the Phase III ConquerRSV study following positive preliminary Phase II data that demonstrates the vaccine’s safety profile.
Shares of Kodiak Sciences plunged nearly 70% in premarket trading after its Phase II/III study of KSI-301 failed to demonstrate non-inferior visual acuity gains compared to Regeneron’s Eylea.
Veru’s enobosarm shows good proof of concept data even when 90% of patients have failed first-line therapies.
Robert LaCaze is taking over the reins of Mnemo Therapeutics with the goal of overcoming key challenges in CAR-T therapies and driving the company’s lead assets into the clinic.
More biotech companies turn to private investors as the market churns volatile for life sciences. Here’s who’s scooping up the cash this week.
Several CEOs have stood out from their peers throughout the past year, winning recognition from the Healthcare Technology Report. BioSpace looks at five of these leaders.
The companies will design and develop targeted gene therapies for a liver-directed rare disease program and conduct additional studies for central nervous system-directed rare disease programs.
GlaxoSmithKline unveiled plans for its new spinout in the consumer health division, Haleon. It is expected to be in place by mid-2022.
Weeks after announcing that its lead monoclonal antibody was demonstrating efficacy against the Omicron variant, Adagio Therapeutics CEO Tillman Gerngross steps down.